Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Activin Receptor Inhibitors—Dalantercept
Shilpa Gupta
, David Gill
, Sumanta K. Pal
, Neeraj Agarwal
Medicine - Hematology, Oncology, Transplant
Research output
:
Contribution to journal
›
Review article
›
peer-review
14
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Activin Receptor Inhibitors—Dalantercept'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Antiangiogenic Therapy
100%
Activin Receptor
100%
ALK1
75%
Dalantercept
75%
Antiangiogenic Agents
50%
Vascular Endothelial Growth Factor
50%
BMP9
50%
Vasculature
25%
In Cancer
25%
Tumor
25%
Preclinical Development
25%
Cancer Therapy
25%
Vascular Development
25%
Safety Profile
25%
Clinical Development
25%
Direct Therapy
25%
Soluble Form
25%
Alternative Pathway
25%
Bone Morphogenetic Protein
25%
Treatment Alternatives
25%
Tyrosine Kinase Receptor
25%
Combination Studies
25%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
25%
Vascular Endothelial Growth Factor Antibody
25%
Ligand Trap
25%
Pharmacology, Toxicology and Pharmaceutical Science
Antiangiogenic Therapy
100%
Activin Receptor
100%
Vasculotropin
75%
Activin Receptor Like Kinase 1
75%
Dalantercept
75%
Bone Morphogenetic Protein 9
50%
Angiogenesis Inhibitor
50%
Malignant Neoplasm
25%
Tyrosine Kinase Receptor
25%
Vasculotropin Antibody
25%
Bone Morphogenetic Protein
25%